Z. Meng

发表

Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.

Patrick J. Curran, M. Williams, Ming Liu, 2010, Bioorganic & medicinal chemistry letters.

A synthetic pathway to either enantiomer of merrilactone A.

S. Danishefsky, Z. Meng, 2005, Angewandte Chemie.

Acid-mediated cyclizations of SEM-protected heterocyclic anilines and adjacent hydroxyls or enol-ethers

M. Siddiqui, Binyuan Sun, P. A. Reddy, 2013 .

Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.

T. Fischmann, Charles E Whitehurst, A. Mcriner, 2013, Bioorganic & medicinal chemistry letters.

Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.

Patrick J. Curran, A. Basso, A. Mandal, 2010, Bioorganic & medicinal chemistry letters.

Development of one-pot synthesis of α-hydroxy α-trifluoromethyl amides

Z. Meng, W. E. Butcher, 2013 .

Discovery of [11C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4 Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases.

Scott T. Harrison, M. Rudd, F. Monsma, 2020, Journal of medicinal chemistry.

Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents.

B. Littlefield, C. Schwartz, Z. Meng, 1999, Bioorganic & medicinal chemistry letters.

Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.

M. Rudd, J. Uslaner, Yongxin Han, 2023, ACS Medicinal Chemistry Letters.

An Expert System Knowledge Base for the Analysis of Infrared Spectra of Organophosphorus Compounds

Zhaoyang Meng, Yuanjun Ma, Z. Meng, 1996 .

Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.

B. Kulkarni, R. Doll, A. Basso, 2011, Bioorganic & medicinal chemistry letters.